




# Update: Bivalent COVID-19 Vaccine Booster Doses

CAPT Jenny Williams, PhD MSN MPH FNP-BC  
October 20, 2022



[cdc.gov/coronavirus](https://cdc.gov/coronavirus)

# Timeline & Steps for Updated Booster



# Bivalent Booster Recommendations

- Everyone ages 5 years and older is recommended to receive 1 age-appropriate bivalent mRNA booster dose two months after completion of any FDA-approved or FDA-authorized monovalent primary series or last monovalent booster dose.
  - People cannot get a bivalent booster without first completing at least a primary series
  - Age-appropriate homologous and heterologous boosters allowed; there is no preference
- At this time, no changes to schedules for children ages 6 months through 4 years.




## Fall Booster “Reset”

- Recommendations are simplified
- Change from dose counting to 1 bivalent booster for everyone eligible
- If eligible, a bivalent should not be denied based on total number of doses


Vaccination history	→	Next dose
Primary series	At least 2 months →	1 bivalent booster dose
Primary series + 1 booster	At least 2 months →	1 bivalent booster dose
Primary series + 2 booster	At least 2 months →	1 bivalent booster dose

# Covid-19 Vaccination Schedule for People who **ARE NOT** Moderately or Severely Immunocompromised


## People ages 6 months through 4 years




## People ages 5 through 11 years



## People ages 12 years and older



## People ages 18 years and older who previously received Janssen primary series dose<sup>†</sup>



\*Administer an age-appropriate mRNA bivalent booster (i.e., Pfizer-BioNTech for people age 5 years and either Pfizer-BioNTech or Moderna for people ages 6 years and older). For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.


<sup>†</sup>Janssen COVID-19 Vaccine should only be used in certain limited situations. See: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a>

# Covid-19 Vaccination Schedule for People who **ARE** Moderately or Severely Immunocompromised


## People ages 6 months through 4 years




## People ages 5 through 11 years



## People ages 12 years and older




## People ages 18 years and older who previously received Janssen primary series dose<sup>†</sup>



## Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

### People ages 12 years and older (must weigh at least 40kg)



\*Administer an age-appropriate mRNA bivalent booster (i.e., Pfizer-BioNTech for people age 5 years and either Pfizer-BioNTech or Moderna for people ages 6 years and older). For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

<sup>†</sup>Janssen COVID-19 Vaccine should only be used in certain limited situations. See: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a>



# Pfizer Covid-19 Products and Dosage

Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Dose	Injection volume
Primary series vaccination						
6 months–4 years‡	Monovalent	Maroon	Maroon	Yes	3 µg	0.2 mL
5–11 years	Monovalent	Orange	Orange	Yes	10 µg	0.2 mL
12 years and older	Monovalent	Gray	Gray	No	30 µg	0.3 mL
Booster vaccination						
5–11 years	Bivalent	Orange	Orange	Yes	10 µg	0.2 mL
12 years and older	Bivalent	Gray	Gray	No	30 µg	0.3 mL

# Moderna Covid-19 Products and Dosage

Age indication	Vaccine composition	Vaccine vial cap color	Label border color	Dilution required	Dose	Injection volume
Primary series vaccination						
6 months–5 years	Monovalent	Dark blue	Magenta	No	25 µg	0.25 mL
6–11 years†	Monovalent	Dark blue	Purple	No	50 µg	0.5 mL
12 years and older	Monovalent	Red	Light blue	No	100 µg	0.5 mL
Booster vaccination						
6–11 years	Bivalent	Dark blue	Gray	No	25 µg	0.25 mL
12 years and older	Bivalent	Dark blue	Gray	No	50 µg	0.5 mL



# Timing Considerations for People with Current or Prior SARS-CoV-2 Infection

- At a minimum, defer any COVID-19 vaccination, including bivalent booster vaccination, at least until recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met.
- In addition, people who recently had SARS-CoV-2 infection may consider delaying any COVID-19 vaccination, including bivalent booster vaccination, **by 3 months** from symptom onset or positive test (if infection was asymptomatic).
- Individual factors such as risk of COVID-19 severe disease, COVID-19 community level, or characteristics of the predominant SARS-CoV-2 strain should be taken into account when determining whether to delay getting a COVID-19 vaccination after infection.

# Coadministration of COVID-19 Vaccines with Other Vaccines



- Routine administration of all age-appropriate doses of vaccines simultaneously is recommended as best practice for people for whom no specific contraindications exist at the time of the healthcare visit.
- Extensive experience with non-COVID 19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.
- **Providers should offer all vaccines for which a person is eligible at the same visit.**

# Coadministration of Influenza with COVID-19 Vaccines



- Providers should offer influenza and COVID-19 vaccines at the same visit, if eligible.
  - This includes adjuvanted or high-dose influenza vaccines; administer in separate limbs.
- With both influenza and SARS-CoV-2 circulating, getting **both vaccines** is important for prevention of severe disease, hospitalization, and death.
- Getting both vaccines at the same visit increases the chance that a person will be up to date with their vaccinations.



## Local and systemic reactogenicity: Moderna bivalent booster



## Local and systemic reactogenicity: Pfizer bivalent booster, ages >55 years




# Update: Monovalent Novavax Booster Authorization

- On October 19, 2022, FDA authorized and CDC recommended use of monovalent Novavax COVID-19 vaccine as a first booster dose to the following individuals at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine
  - Individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate,
  - Individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.
- Same formulation and dose as what is currently used for primary vaccination
- CDC Interim Clinical Considerations are posted




# Percent of population eligible for a booster dose who have received a first booster dose, October 19, 2022



Source: [https://covid.cdc.gov/covid-data-tracker/#vaccinations\\_vacc-people-additional-dose-totalpop](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-additional-dose-totalpop) Accessed Sept 28, 2022



# Completed primary series and 1st boosters by age group for persons ages 5-49 years, United States, December 2020 – August 2022



Source: CDC IZDL; Accessed 8/22/22; First boosters does not include Texas for all ages or Idaho for ages <18

# Resources

Fall 2022 Updated COVID-19 Vaccine Rollout



# Vaccines.gov update

- Flu vaccines are now on the Vaccines.gov search experience
- One site with search for both COVID-19 and flu vaccines
- Updated COVID-19 booster search fields will be added once distribution begins
- **Minimum age for vaccine administration by location is now available**



Vaccines.gov

Menu

Need help finding a COVID-19 vaccine in the U.S.?  
Call [1-800-232-0233](tel:1-800-232-0233) (TTY [1-888-720-7489](tel:1-888-720-7489))



## Find a COVID-19 vaccine near you

Use Vaccines.gov to find a location near you, then call or visit their website to make an appointment.

[Find COVID-19 Vaccines & Boosters](#)

[I'm looking for flu vaccines](#) →

Powered by VaccineFinder



# Interim Clinical Considerations and FAQs

## Interim Clinical Considerations

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>

## Frequently Asked Questions

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html>



# Resources for general public and immunization partners

- **\*NEW\*** [Resources to Promote COVID-19 Vaccines for Children & Teens](#) (includes social media graphics, posters, videos, external partner resources)
- [Stay Up to Date with Your COVID-19 Vaccines | CDC](#)
- [COVID-19 Vaccines for Children and Teens](#)
- [COVID-19 Vaccines for People who are Moderately or Severely Immunocompromised | CDC](#)
- [COVID-19 booster tool](#)
- [Coronavirus \(COVID-19\) Update: FDA Recommends Inclusion of Omicron BA.4/5 Component for COVID-19 Vaccine Booster Doses | FDA](#)




# Resources for jurisdictions, clinicians, vaccine providers, and community partners:

- [Promoting COVID-19 Vaccine in Long-term Care Settings](#) (Info for LTC Administrator and Managers, as well as Jurisdictions)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines](#)
- [Ways Health Departments Can Help Increase COVID-19 Vaccinations | CDC](#) Guide for local outreach and other resources for public affairs, including “[How to Address COVID-19 Vaccine Misinformation](#),” “[How to Tailor COVID-19 Information to Your Specific Audience](#)” and “[Talking to Patients with Intellectual and Developmental Disabilities about COVID-19 Vaccination](#)”
- [Vaccinate with Confidence](#) Strategies for reinforcing confidence in COVID-19 vaccines
- [What to Consider When Planning to Operate a COVID-19 Vaccine Clinic](#)



For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)



The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.